SPARX: Safety and efficacy of sparsentan for patients post kidney transplantation with IgAN or FSGS
Protocol Name: SPARX: Safety and efficacy of sparsentan for patients post kidney transplantation with IgAN or FSGS Protocol #: TVTX-RE021-426 Indication: Cardiovascular Event Risk Reduction GFR: ≥25 Principal Investigator: Bernard Fischbach, MD, CCRP Location: Dallas Transplant Institute, 3604 Live Oak Street, Suite 100, Dallas, TX 75204 DETAILS >